Annual BioTech Breakthrough Award is devoted to honoring excellence in life science and biotechnology solutions, services, ...

Boehringer Ingelheim, a leading research-driven biopharmaceutical company, has been lifted to 8th place in the 2024 Access to ...

The Freedom Alert Max empowers seniors through proprietary, 4G LTE mobile technology as the first fall detection device with ...

Biopharma Leaders of Color (BLOC), a 501 (c) (3) non-profit organization dedicated to promoting the professional advancement of people of color and growing the representation of leaders from ...

With over 20 years of experience in autism and education fields, Emily Patrizi is a Board Certified Behavior Analyst who brings extensive clinical and operational expertise to Stride. Recently, she ...

MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to ...

The dual listing on Upstream is designed to provide Kairos Pharma the opportunity to access a global investor base outside the U.S., unlocking liquidity and enhancing price discovery while globalizing ...

NIH-funded Phase 2-3 ALS Expanded Access study expands reach of MediciNova’s ongoing COMBAT-ALS trial and provides illustration of Company’s development strategy LA JOLLA, Calif., Nov. 19, 2024 (GLOBE ...

Today, Georgiamune Inc., a privately held, clinical-stage biotechnology company, announces the appointment of Mark Avagliano as Chief Business Officer. The news comes as Georgiamune closes out 2024 ...

Project is part of the U.S. Department of Defense’s BioMADE initiative to support U.S. bioindustrial manufacturing innovations and workforce development Monrovia, CA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- ...

By leveraging AI-powered technology, remote monitoring, and fewer physical aligners, Dror Ortho-Design is paving the way for a greener future in dental care. Lee Haddad, CEO of Dror, highlighted the ...

Univest, LLC is acting as the exclusive placement agent for the offering. The offering is expected to close on or about November 19, 2024, subject to satisfaction of customary closing conditions.